electroCore, Inc. (ECOR)

NASDAQ: ECOR · Real-Time Price · USD
15.27
+0.75 (5.17%)
Dec 20, 2024, 4:00 PM EST - Market closed
5.17%
Market Cap 100.09M
Revenue (ttm) 23.33M
Net Income (ttm) -12.69M
Shares Out 6.55M
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 197,727
Open 14.40
Previous Close 14.52
Day's Range 14.27 - 16.20
52-Week Range 5.25 - 17.84
Beta 0.58
Analysts Strong Buy
Price Target 25.00 (+63.72%)
Earnings Date Nov 13, 2024

About ECOR

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general healt... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 22, 2018
Employees 68
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2023, electroCore's revenue was $16.03 million, an increase of 86.57% compared to the previous year's $8.59 million. Losses were -$18.83 million, -15.02% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ECOR stock is "Strong Buy" and the 12-month stock price forecast is $25.0.

Price Target
$25.0
(63.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector

3 days ago - GlobeNewsWire

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in ...

5 weeks ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call...

5 weeks ago - Seeking Alpha

electroCore Announces Third Quarter 2024 Financial Results

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales

5 weeks ago - GlobeNewsWire

ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award

ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness prod...

5 weeks ago - GlobeNewsWire

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freebur...

6 weeks ago - GlobeNewsWire

electroCore to Participate at LD Micro Main Event VXII

Rockaway, New Jersey--(Newsfile Corp. - October 14, 2024) - electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will parti...

2 months ago - Newsfile Corp

Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training

Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor le...

3 months ago - GlobeNewsWire

electroCore to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ROCKAWAY, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in th...

3 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q2 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - La...

4 months ago - Seeking Alpha

electroCore to Participate in Upcoming Investor Conferences

ROCKAWAY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's CEO, Dan Goldberg...

4 months ago - GlobeNewsWire

electroCore Announces Second Quarter 2024 Financial Results

Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023  Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY...

4 months ago - GlobeNewsWire

electroCore Announces the Commercial Launch of TAC-STIM™

ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf...

6 months ago - GlobeNewsWire

electroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

ROCKAWAY, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced tha...

7 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q1 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - Laden...

8 months ago - Seeking Alpha

electroCore Announces First Quarter 2024 Financial Results

Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST

8 months ago - GlobeNewsWire

electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results...

8 months ago - GlobeNewsWire

Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion

ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its...

8 months ago - GlobeNewsWire

electroCore Announces the Launch of Truvaga Plus® for General Wellness

ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consume...

9 months ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue n...

9 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q4 2023 Earnings Call Transcript

electroCore, Inc. (ECOR) Q4 2023 Earnings Call Transcript

10 months ago - Seeking Alpha

electroCore Announces Fourth Quarter and Full Year 2023 Financial Results

Record full year 2023  net sales of $ 16.0 million increased 87%  over $8.6  million for the full year 2022

10 months ago - GlobeNewsWire

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial resul...

10 months ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Tradema...

1 year ago - GlobeNewsWire

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical Off...

1 year ago - GlobeNewsWire